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Abstract: During the past decade, transdermal delivery systems (TDS) have become 
increasingly important for treating neurologic and psychiatric disorders. The rivastigmine 
patch was the ﬁ  rst patch to be approved to treat Alzheimer’s disease (AD). The 9.5 mg/24 h 
patch has equal efﬁ  cacy to the capsules and reduces gastrointestinal adverse events, such as 
nausea and vomiting, by two-thirds. This treatment is well tolerated by patients because drug 
delivery is even and continuous, reducing ﬂ  uctuation in drug plasma level, and attenuating the 
development of centrally mediated cholinergic side effects. Furthermore, once-a-day application 
of the patch enables an easy treatment schedule, ease of handling, infrequent skin irritations, 
and a patient- and caregiver-friendly mode of administration. Improved compliance with a 
subsequent drug administration may contribute to better clinical efﬁ  cacy, reduce caregiver 
burden, result in a slower rate of institutionalization, and lead to a decrease in healthcare and 
medical costs. Because of these advantages, the rivastigmine patch has enabled great prog-
ress in the treatment of AD, and represents an excellent alternative to the orally administered 
cholinesterase inhibitors.
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Introduction
The ﬁ  rst transdermal delivery system, a patch to treat sea sickness based on the 
agent scopolamine (Transderm Scop®), was approved in the 1970s. To date, various 
transdermal patches to treat neurological and psychiatric diseases have been approved, 
including methylphenidate (DaytranaTM) to treat attention deﬁ  cit hyperactivity disorder, 
rotigotine (Neupro®) to treat Parkinson’s disease, selegiline (Emsam®) to treat 
depression, and fentanyl (Durogesic®) for pain. In July 2007 the rivastigmine patch was 
approved to treat mild to moderate AD and Parkinson-associated dementia (US Food 
and Drug Administration 2008). TDS has several advantages. Continuous release, for 
example, enables a constant drug plasma level, which may be a beneﬁ  t when treating 
Parkinson’s disease, assuming that a brief stimulation of the dopamine receptor in 
particular is responsible for the development of L-Dopa-associated motor complica-
tions (Fabbrini et al 2007). Because the drug absorption is independent of ingestion and 
gastrointestinal interactions, the incidence of adverse gastrointestinal effects may be 
reduced. The ﬁ  rst-pass effect can also be circumvented (Oertel et al 2007). Furthermore, 
transdermal administration allows the application of drugs with a short half-life and a 
low therapeutic index. And in case of an accidental overdose, an effective disruption 
of transdermal administration is possible.
The easy employment of the patches, with usually only a once-daily change, 
increases patient compliance. Furthermore, the caregivers can inspect the application 
of the patch. Improved compliance of the patient, and thus intake of the agent, is a 
signiﬁ  cant beneﬁ  t in the treatment of AD (Small et al 2005; Oertel et al 2007). One 
disadvantage of the TDS is a possible skin reaction. In one clinical trial the application Drug Design, Development and Therapy 2008:2 246
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of the rotigotine patch caused local skin reactions in 44% of 
patients, although only 5% interrupted the treatment because 
of this side effect (Watts et al 2007).
The aim of this article is to provide an overview on the 
relevance of the rivastigmine patch as a therapeutic option 
for AD.
Treatment of Alzheimer’s disease
Evidence shows that current treatment with acetylcholin-
esterase inhibitors (AchEIs) and memantine may have a 
beneﬁ  cial effect on AD, encouraging early diagnosis and 
treatment (Farlow et al 2000; Raskind et al 2004; Farlow 
and Cummings 2007). The American Psychiatric Association 
asks for an effect in four domains in the treatment of AD: 
improvement of cognitive functions, activities of daily living, 
exposure of the caregivers, and the global overall impression. 
Only the AchEIs, rivastigmine, galantamine, and donepezil, 
and the NMDA-receptor antagonist memantine, meet these 
criteria and are currently approved to treat AD. Possible 
beneﬁ  ts for behavioral disturbance, institutionalization, 
mortality, disease related quality of life, and the incidence 
of side effects should also be assessed.
Acetylcholinesterase inhibitors
The ﬁ  rst AchEI, tacrine, a reversible, nonselective inhibitor, 
has shown an improvement in cognitive functions in patients 
suffering from AD (Summers et al 1986) and was approved 
for the treatment of AD in 1993 by the FDA. Because of 
severe cholinergic effects, a pronounced hepatotoxicity, and a 
difﬁ  cult dosing schedule, this drug is rarely prescribed today 
and has even been deregistered in some countries. The three 
drugs of the second generation, donezepil, rivastigmine, and 
galantamine, are characterized by fewer adverse effects and 
an easier dosing schedule.
The different and adverse effects of the three AchEIs are 
the result of unequal pharmacodynamic and pharmacokinetic 
characteristics (Table 1).
The three AchEIs compensate for the cholinergic deﬁ  cit in 
the synaptic clefts and increase cholinergic neurotransmission, 
which is reduced in patients with AD (Scarpini et al 2003). 
While donezepil only selectively and reversibly inhibits 
acetylcholinesterase, the selective and reversible AchEI 
galantamine has an allosterical stake on the nicotinergic 
acetylcholine receptor, and thus enhances the effect of acetyl-
choline receptor agonists on cholinergic transmission (Scott 
and Goa 2000). In addition to a pseudo-irreversible inhibition, 
rivastigmine also affects the activity of butyrylcholinesterase 
(BchE) (Xie et al 2000), which forms up to 10% of the cholin-
esterase in the human brain. This enzyme is mainly found in 
glial cells, but also occurs in neurons, endothelial tissue, and 
synaptic clefts. BchE can compensate for the AchE-associated 
effect after deletion of the AchE gene in mice (Xie et al 2000). 
During the course of AD the activity of AchE decreases, while 
the BchE activity remains constant or increases (Perry et al 
1978), which suggests that rivastigmine also has a role in 
the treatment of an advanced stage of the disease. Moreover, 
there is evidence that BchE plays a major role in certain 
cognitive functions. The results of one multiple-dose study 
have shown that the inhibition of BchE activity, but not that of 
AchE, in the cerebrospinal ﬂ  uid correlated signiﬁ  cantly with 
an improvement in attention, speed, and memory. Another 
crucial difference between rivastigmine and the other AchEIs, 
is the priority selective effect of the G1-subtype of AchE, 
which occurs particularly in the amygdala, hippocampus, and 
Table 1 Characteristics of the three cholinesterase inhibitors
Rivastigmine Donezepil Galantamine
Dosage 3–12 mg/day 5–10 mg/day 8–24 mg/day
Pharmacodynamics Inhibition of AchE and BchE Inhibition of AchE Inhibition of AchE, allosteric modulation 
of nicotinergic Ach receptor
Pharmacokinetics
Bioavailability 36% 43% 88%
Protein binding 40% 90% 18%
t1/2 0.6–2 hours 70 hours 8–10 hours
tmax 1 hour 3–4 hours 4.4 hours
CYP metabolism Yes Yes Minimal
Elimination 95% renal 79% renal 95%–97% renal
Adverse events Nausea, vomiting, diarrhea, weight 
loss, dizziness, tiredness, tremor
Nausea, vomiting, diarrhea, tiredness, 
muscular cramps, bradycardia
Nausea, vomiting, diarrhea, dyspepsia, 
tremor, weight loss
Abbreviations: AchE, acetyl cholinesterase; BchE, butyrylcholinesterase; CYP, cytochrome.Drug Design, Development and Therapy 2008:2 247
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cortex regions of the brain, which are especially involved in 
AD (Polinsky 1998). The G1-subtype of AchE seems to have 
an exceptional role in the development of AD. In contrast, 
donezepil and galantamine primarily inhibit the G2- and G4-
subtype of AchE, which are usually found in the basal ganglia 
and outside the central nervous system. This difference could 
be responsible for the fewer extrapyramidal-motoric, cardiac, 
and muscular side effects of rivastigmine.
In accordance with current studies, the German Institute 
for Quality and Efﬁ  ciency in Health Care (IQWiG) reached 
the conclusion that donezepil, rivastigmine, and galantamine 
lead to an improvement of cognition, activities of daily 
living, and global overall impression (Institute for Quality 
and Efﬁ  ciency in Health Care 2007). The annual report of the 
IQWiG for galantamine notes evidence of an improvement in 
behavioral disturbance, quality of life of caregivers, and men-
toring effort. Because of negative study results or the lack of 
well-designed studies, there is no evidence of a positive inﬂ  u-
ence on the institutionalization, mortality, and disease related 
quality of life for one of the three drugs (Institute for Quality 
and Efﬁ  ciency in Health Care 2007). Signiﬁ  cant improve-
ment of the cognitive functions measured on the Alzheimer’s 
Disease Assessment Scale (ADAS-cog) (Rosen et al 1984) by 
patients suffering from mild to moderate AD, was supported 
in two randomized, placebo-controlled trials (Corey-Bloom 
et al 1998; Rosler et al 1999). Both trials found a signiﬁ  cant 
improvement in only the high-dose groups, with a dosage of 
6 to 12 mg rivastigmine daily, compared with the placebo 
group (Corey-Bloom et al 1998: ADAS-cog p  0.01; Rosler 
et al: p = 0.011 [Institute for Quality and Efﬁ  ciency in Health 
Care 2007]). To evaluate daily living activity, the Progres-
sive Deterioration Scale (PDS) was used in both trials. In 
the Corey-Bloom et al clinical trial, a signiﬁ  cant improve-
ment in activities of daily living was observed in the high 
dosage group (6–12 mg daily), while in the low dose group 
(1–4 mg daily) no signiﬁ  cant difference, compared with the 
placebo group, was noticed. In the Rosler et al trial, only an 
insigniﬁ  cant beneﬁ  t of rivastigmine was detected in the high 
dose group (p = 0.07) (Rosler et al 1999).
In both trials, global functioning under treatment with 
rivastigmine was measured with the Clinican’s Interview 
Based Impression of Change Plus Caregiver Input (CIBIC-
Plus). In the Rosler et al trial, a signiﬁ  cant increase in patients 
with improved global function was observed in 37% of the 
high dose group, and 30% of the low dose group, compared 
with the placebo-treated group. The Corey-Bloom et al trial 
registered a pronounced improvement in global function in 
the low and high dose groups (Corey-Bloom et al 1998).
Under the guidelines of the National Institute for Health 
and Clinical Excellence (NICE), the studies found a signiﬁ  cant 
improvement in cognition and global outcomes after treat-
ment with donezepil. The evidence for an effect on the quality 
of life, and on behavioral disturbance, was less conclusive. 
Only a short-term beneﬁ  t was suggested for the functional 
outcome. According to the NICE guidelines, the studies 
found evidence for an improvement in cognition, functional 
outcomes, and activities of daily living for treatment with 
galantamine, but after the Assessment Group had pooled the 
studies, an improvement in global outcome was not approved. 
One study showed a signiﬁ  cant improvement in behavior with 
a higher galantamine dosage (16 mg/day). For rivastigmine, 
the trials suggest an improvement in cognition and global 
outcome, while no signiﬁ  cant beneﬁ  t for behavior, and a 
less conclusive effect on functional outcomes, was reported 
(NICE 2007). To date, no placebo-controlled, randomized tri-
als have been published, which show a signiﬁ  cant difference 
between rivastigmine and placebo for the caregiver burden, 
or in behavioral disturbance of patients, institutionalization, 
mortality, and the health-related quality of life (Institute for 
Quality and Efﬁ  ciency in Health Care 2007).
Development of other therapy
options for Alzheimer’s disease
In the past few years, knowledge of the pathophysiology of 
AD has sharply increased, opening doors for positive research 
on new therapeutic options.
It is generally accepted that the cerebral accumulation of 
the amyloid-β peptide (Aβ) plays an important role in the 
pathogenesis of AD. Aβ is inherently neurotoxic in vitro 
and is indirectly responsible for neuronal death (Cummings 
2004), because of a secondary initiation of inﬂ  ammation, 
oxidation, hyperphosphorylation of tau protein, and glutama-
tergic excitotoxicity (Hardy and Selkoe 2002). Accordingly, 
the prevention of the production and aggregation of Aβ could 
be an effective target for drugs. With the aim of avoiding 
the production of Aβ, the development of secretase inhibi-
tors, which retard the processing of the amyloid precursor 
protein, have become a promising subject of research 
(Dewachter and Van Leuven 2002). Short synthetic peptides 
have been devised with the aim of stopping the aggregation 
of amyloid plaques, which prevent the connection of Aβ 
(Permanne et al 2002; Soto et al 2000).
Another auspicious target for future treatment of AD 
is passive and active immunization against Aβ. In older 
transgenic mice, research showed that an active immunization 
with an intraperitonal application of Aβ1–42 reduced the Drug Design, Development and Therapy 2008:2 248
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burden of amyloid plaques, and that this was linked to the 
development of Aβ antibodies (Schenk et al 1999). However, 
a clinical trial using Aβ1–42 as antigen has ceased, because 
6% of the patients developed encephalitis (Orgogozo et al 
2003). There is evidence that passive immunization, using 
antibodies against Aβ, also reduced the amyloid plaques 
(Dodel et al 2003). Both active and passive immunizations 
led to a cognitive recovery in mouse models (Morgan et al 
2000; Dodart et al 2002).
Furthermore, treatment with statins seems to prevent 
AD (Puglielli et al 2003). By reduction of the intracellular 
cholesterol, statins might inhibit the accumulation of amyloid 
plaques, and may also ameliorate amyloid plaque-associated 
inﬂ  ammation (Crisby et al 2002).
Studies have shown that long-term use of certain NSAIDs 
may reduce the incidence of AD (McGeer et al 1996, in t`Veld 
et al 2001), but are unable to improve the symptoms in patients 
suffering from AD (van Gool et al 2003). The protective effect 
of certain NSAIDs such as indomethacine could be linked 
to an inhibition of cyclooxygenase and to the processing of 
β-amyloid precursor protein (Weggen et al 2001).
Pre-clinical efﬁ  cacy
of the rivastigmine patch
Patch structure
Patches could be either topical, for a local effect only, or 
based on TDS for transdermal systemic release of the drug. 
TDS in particular have become important in the treatment 
of neurological diseases in recent years. In contrast to 
conventional reservoir patches, matrix patches with a 
polymer layer enable admission of a larger amount of the 
drug, and therefore, production of smaller patches.
Rivastigmine is a 2.6-dioxo-4-phenyl-piperidine-3-
carbonitrile. Its chemical formula is shown in Figure 1. The 
small molecular weight of 250.34 Da, the lipophil, and the 
hydrophil characteristics, along with the potent effect of even 
very small portions, established the explicit aptitude of the 
drug for application with TDS.
The rivastigmine patch is composed of four layers 
(Figure 2). The highest layer, the backing ﬁ  lm, is colored 
and has a protective function against mechanical, extrane-
ous causes. In the second layer, the drug is incorporated 
into an acrylic matrix, which ensures effective storage of 
rivastigmine (Oertel et al 2007). The next coating, a silicone 
matrix layer with a silicone polymer, provides good adhesion 
of the patch to the skin. Directly on the skin, a release liner 
guarantees continuous dispensing of the drug through the 
skin, providing smooth delivery into the bloodstream. This 
layer also minimizes skin reactions.
Dosage and patch application
Two different patches are available. The smaller 5 cm2 
patch contains a total dose of 9 mg rivastigmine and 
releases 4.6 mg/day rivastigmine. The 10 cm2 patch 
has a capacity of 18 mg rivastigmine, and releases 
9.5 mg/day. Therapy should begin with the small patch 
of 4.6 mg/24 h and, if well tolerated, the dose could be 
increased after a minimum of 4 weeks to the 9.5 mg/24 h 
patch (Figure 3).
If the drug cannot be tolerated because of side effects such 
as nausea, therapy can be interrupted, or the dosage reduced. 
If the patch application is discontinued for more than seven 
days, the treatment should start with the 4.6 mg/24 h patch. 
Oral treatment may be directly switched for the transdermal 
application (oral dosage 6 mg to the 4.6 mg/24 h patch, 
oral dosage from 6 to 12 mg to the 9.5 mg/24 h patch). No 
dosage reduction is necessary in patients with renal or hepatic 
disturbance.
However, the rivastigmine patch should be applied only 
on uninjured, clean, dry, and hairless skin. The upper back, 
chest or the forearm are especially well suited for applica-
tion. The skin should be cleaned only with water, and soap 
residues should be avoided. Swimming and sports are also 
possible, although heat and sun exposure should be avoided 
for long periods of time (Novartis 2007).
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Figure 1 Chemical structure of rivastigmine (adapted from Cummings and Winblad 
2007).
Layer 1 Backing film
Layer 2 Acrylic matrix
Layer 3 Silicone matrix
Layer 4 Release liner
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Pharmacokinetics
Three placebo-controlled trials have investigated the 
different pharmacokinetic profile of the patch and the 
capsule formulation (Lefevre et al 2007; Lefevre et al 
2008; Mercier et al 2007). The rivastigmine patch provides a 
continuous and smooth release of the drug. After application of 
the ﬁ  rst patch, the absorption of the drug begins after a time-lag 
of 0.5 to 1 h (Lefevre et al 2008). The maximum plasma level 
of rivastigmine is reached after a mean of 8 h. After this point, 
drug concentration reduces only slowly, so that ﬂ  uctuation 
of the plasma level in transdermal administered rivastigmine 
is low. At a steady state, the trough level of the drug after 
transdermal application is 60%–80% of the maximum plasma 
level. In contrast, after oral administration with the capsule 
formulation for all doses, the plasma peak is reached after 
just 1 h, followed by a rapid decline in plasma levels (Hossain 
et al 2002). The maximum concentration after a 3 mg capsule 
twice daily is approximately 70% higher than after using the 
9.5 mg/24 h patch. Therefore, ﬂ  uctuating plasma concentration 
after oral administration is accelerated more sharply than after 
patch application (ﬂ  uctuation index: 6.2 for twice daily 3 mg 
and 4.0 for twice daily 1.5 mg oral administration; 0.6 for the 
4.6 mg/24 h patch and 0.8 for the 9.5 mg/24 h patch) (Figure 4) 
(Lefevre et al 2008).
The measured drug exposure after application of the 
9.5 mg/24 h patch is close to rivastigmine exposure after 
administration of 3 mg twice daily. The drug delivery rate of 
the two patches amounts to approximately 50% (Lefevre et al 
2008). The delivery rate and the maximum drug concentration 
are dependent on the region of application of the patch. 
Compared with the upper back, the relative bioavailability of 
the drug is 100% for the chest, 92% for the upper arm, 80% 
for the abdomen, and 71% for the thigh (Lefevre et al 2007). 
Thus the highest exposure rate of plasma concentration can 
be reached on the chest, upper back, and upper arm.
Rivastigmine binds low (approximately 40%) to the 
plasma proteins and has an apparent distribution volume 
of 1.8 to 2.7 L/kg. Following transdermal administration, 
rivastigmine is metabolized by AchE and BchE-mediated 
hydrolysis to the principal metabolite NAP226-90. In vitro, 
NAP226-90 inhibits AchE to a minimal extent (10%) 
(Polinsky 1998). There is evidence that rivastigmine is 
present in only a very small amount metabolized by the 
hepatic cytochrome P-450 system, which could be the 
reason for the minimal interaction potential of the drug 
(Polinsky 1998). After transdermal administration, less 
NAP226-90 is formed compared with oral administration, 
indicating that metabolization of transdermally admini-
stered rivastigmine is lower than after intake of the capsules. 
This difference is attributed to the distinct hepatic ﬁ  rst-pass 
effect after oral administration, which is responsible for 
the low bio  availability (~35%) after oral administration 
(Polinsky 1998). The assumption of greater efﬁ  cacy for 
transdermal rivastigmine is based on lower metaboli  zation 
into the lesser potent NAP226-90, compared with oral 
administration. Both oral and transdermal administration 
underlie a nonlinear pharmacokinetic mechanism, due to 
the saturation of the rivastigmine-metabolizing enzymes 
(Hossain et al 2002).
The principal metabolites of the drug are renally excreted; 
only 1% of the drug is eliminated through the feces, and 
only traces of unchanged rivastigmine are found in the 
urine.
After removal of the patch the elimination half-time 
amounts to approximately 3 h.
Interactions
The interaction potential of the rivastigmine patch has not 
been investigated in a clinical study. But because of the very 
5 cm2 10 cm2 4 weeks
4.6 mg/24 h 9.5 mg/24 h
Figure 3 Dosage of the rivastigmine patch (adapted from Cummings and Winblad 
2007).
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Figure 4 Drug concentration over the time after administration of the patch or 
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small interaction with the cytochrome P450 system, only a 
marginal interaction potential is to be expected.
Adverse effects
Gastrointestinal side effects such as vomiting, nausea, diarrhea, 
and other cholinergic side effects are a frequent problem 
in treatment with AchEIs especially in the titration phase. 
Gastrointestinal side effects sometimes result from fast titration 
of the drug, particularly when rivastigmine is administrated 
orally, thereby circumventing the administration of the 
maximal admitted dosage and leading to discontinuation of 
the treat  ment. This result is especially important, because 
meta-analyses have shown that rivastigmine exerts a deﬁ  nite 
clinical effect only at higher doses (Institute for Quality 
and Efﬁ  ciency in Health Care 2007). There is evidence 
that cholinergic side effects are the result of an abrupt rise 
in stimulation of the acetylcholine receptor in the brain 
after administration of the rivastigmine capsules (Lefevre 
et al 2008; Yang and Keating 2007).
This problem accelerated the development of other 
formulations of rivastigmine. The rivastigmine patch theoret-
ically offers, with continuous release of the drug and constant 
plasma drug level, the strongest possibility of minimizing 
ﬂ  uctuation-associated side effects (Cummings and Winblad 
2007). And indeed, in clinical trials the patch-treated patients 
develop fewer adverse gastrointestinal effects than patients 
treated with capsules at 3 to 12 mg/day (Winblad et al 2007a). 
Table 2 shows the different proﬁ  les of adverse effects of the 
two formulations.
Contraindictions
The rivastigmine patch is contraindicated in patients with 
known intolerance of rivastigmine, or other constituents of 
the TDS. No clinical studies have been conducted on pregnant 
woman and nursing mothers. Patients with low body weight 
should be carefully monitored due to the incidence of more 
adverse effects, and the possibility of more weight loss caused 
by rivastigmine.
Clinical efﬁ  cacy of the rivastigmine 
patch
Effects
To evaluate the clinical efﬁ  cacy, the available literature was 
systematically reviewed. In order to identify relevant studies, 
we searched keywords such as “rivastigmine”, “Alzheimer”, 
“patch” along with combinations of these in the following 
databases: Pubmed (January 1997–December 2007), the 
databases of the Centre for Reviews and Dissemination 
(until December 2007), and the database of the Deutsches 
Institut für medizinische Dokumentation und Information 
(DIMDI) (until December 2007). In addition, we screened 
the following journals for abstracts: Annals of Neurology, 
European Journal of Neurology, Neurology, Journal of 
Neurology. Abstracts were considered only when a) they 
were in English/German/Spanish/French and b) an evaluation 
of rivastigmine was explicitly mentioned. Four studies were 
identiﬁ  ed in which the rivastigmine patch was assessed in 
patients suffering from AD.
The clinical efficacy of the rivastigmine patch 
was investigated in the IDEAL study (Investigation of 
Transdermal Exelon® in AD) (Winblad et al 2007a; Winblad 
et al 2007b).
The IDEAL study was a 24-week, randomized, 
double-blind, double-dummy, placebo- and active controlled, 
multicenter trial of the rivastigmine patch on 1195 AD 
patients. The patients were randomized in one of four groups 
with target doses of: 9.5 mg/24 h (10 cm2) rivastigmine 
patch (n = 293), 17.4 mg/24 h (20 cm2) rivastigmine patch 
(n = 303), 3 mg/day to a maximum of 12 mg/day rivastigmine 
capsules (n = 297) or placebo (n = 302). The patches were 
Table 2 Adverse events reported in the IDEAL-study (safety population)
Adverse event 10 cm2 patch 20 cm2 patch Capsules Placebo
Nausea 7% 21% 23% 5%
Vomiting 6% 19% 17% 3%
Diarrhea 6% 10% 5% 3%
Weight loss 3% 8% 5% 1%
Dizziness 2% 7% 8% 2%
Decreased appetite 1% 5% 4% 1%
Headache 3% 4% 6% 2%
Astenia 2% 3% 6% 1%Drug Design, Development and Therapy 2008:2 251
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placed by the caregivers on the upper back every morning, 
with normal daily activities like bathing being permitted. 
The patients were investigated at baseline, week 16 and 
week 24. The primary outcomes were a change from base-
line to week 24 in the Alzheimer’s Disease Assessment 
Scale-Cognitive subscale (ADAS-Cog) (Rosen et al 
1984) and, to assess the global impression of the patient, 
a change from baseline to week 24 in the Alzheimer’s 
Disease Cooperative Study-Clinical Global Impression of 
Change (ADCS-CGIC) (Schneider and Olin 1996). Com-
pared to placebo, all rivastigmine-treated patients (patches 
and capsules) at week 24 showed a signiﬁ  cant improve-
ment in the ADAS-Cog score and a signiﬁ  cant reduction in 
ADCS-CGIC scores, indicating an improvement of cogni-
tive functions and global impression. Secondary outcomes 
comprise the Mini Mental State Examination (MMSE) 
(Folstein et al 1975), Neuropsychiatric Inventory (NPI-12, 
with the NPI-Distress), psychiatric disturbance and behaviour 
(Cummings et al 1994), Alzheimer’s Disease Cooperative 
Study Activities of Daily Living Inventory (ADCS-ADL) 
(Galasko et al 1997), Trail Making Test Part A (TMTA) 
(motor processing speed, attention, and visual tracking) 
(Corrigan and Hinkeldey 1987), and the Ten-Point Clock-
Drawing Test (TCD) (executive and visuospatial functions) 
(Watson et al 1993). Compared with placebo, the 10 cm2 and 
the 20 cm2 rivastigmine patches and the rivastigmine capsules 
led to a signiﬁ  cant improvement in results for the ADCS-
ADL, MMSE, and the TMTA at week 24. No signiﬁ  cant 
difference was observed in the NPI-12, NPI-Distress score, 
and TCD in the 3 rivastigmine-treated groups compared with 
the placebo group at week 24. There was no statistical differ-
ence between the efﬁ  cacy of the rivastigmine capsules and 
the 10 cm2 patch. Compared with the patients treated with the 
10 cm2 patch, the 20 cm2 patch group showed numerically 
better scores on the ADAS-Cog at week 24.
Adverse effects
The most reported side effects in AchEI treatment are 
cholinergic side effects such as nausea, vomiting, and diar-
rhea. In the IDEAL study of 1195 patients, adverse events in 
the four groups: 10 cm2 rivastigmine patch, 20 cm2 rivastig-
mine patch, capsule (3 to 12 mg rivastigmine per day), and 
placebo, were analyzed (Winblad et al 2007a; Winblad et al 
2007b) (Table 2). Patients in the 10 cm2 patch group devel-
oped nearly two-thirds fewer nausea (7%) and vomiting (6%) 
reactions than the 20 cm2 patch group (21% nausea, 19% 
vomiting), and the patients receiving capsules (23% nausea, 
17% vomiting). After administration of the 20 cm2 patch and 
the capsules, signiﬁ  cantly more adverse effects were noted 
than in the placebo group. The incidence of adverse events 
in the 10 cm2 patch-treated group did not differ statistically 
from the placebo group. The reported side effects were 
mainly mild to moderate.
Because of adverse events, 10% of the patients in 
the 20 cm2 group, 11% in the 10 cm2 group, and 9% of 
patients in the placebo group, have discontinued the trial. 
Severe adverse events occurred in 8% of patients receiving 
the 10 cm2 patch, 12% receiving the 20 cm2 patch, 7% receiv-
ing the capsules, and 9% receiving placebo.
Weight loss equal to or more than 7% of the baseline 
weight was observed in 8% of the patients of the 10 cm2 
patch group, 12% of the patients receiving the 20 cm2 patch, 
11% of the patients treated with the capsules, and 6% of the 
patients receiving placebo.
In conclusion, in the IDEAL study, the 10 cm2 patch 
was well tolerated. In contrast to the 20 cm2 patch and the 
capsules, the incidence of side effects was not signiﬁ  cantly 
different compared with the placebo. Moreover, in a study 
including 40 healthy volunteers, the 10 cm2 patch was also 
well tolerated (Lefevre et al 2007). In the IDEAL study, skin 
irritation was rarely reported. Skin irritation was assessed by 
the investigators and caregivers: 8% of patients receiving a 
patch (all sizes) and 4% receiving the placebo patch devel-
oped an erythema; 7% of the patch-treated group and 3% of 
the placebo patch group reported pruritus; 2% of patients 
treated with a patch, and no patients from the placebo group, 
discontinued the treatment because of skin irritation (Winblad 
et al 2007a). Another study investigated the tolerance of the 
patch on different regions of the body (Lefevre et al 2007). 
More incidents of erythema occurred when the patch was 
applied to the thigh and abdomen (compared with the upper 
back), whereas patch adherence to the upper arm and the 
chest led to fewer such incidents. Erythemic instances were 
marginal, visible, or mild, and self-resolved within 24 h of 
patch displacement. No other skin reactions, such as papules 
or edema, were observed (Lefevre et al 2007).
Caregiver
In a sub-study of the IDEAL trial, the caregiver preference 
for the rivastigmine patch, compared with capsule treatment, 
was investigated (Winblad et al 2007c). At baseline, week 8 
and week 24, the AD Caregiver Preference Questionnaire 
(ADCPQ) (Winblad et al 2007c) was used to evaluate the 
satisfaction, preferences, and expectations of the caregivers. 
The double-dummy nature of the study ensured that this 
assessment was not inﬂ  uenced by perceptions of efﬁ  cacy Drug Design, Development and Therapy 2008:2 252
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and tolerability (Winblad et al 2007c). At week 8, 68% 
of the caregivers preferred the patch over the capsules. 
At week 24, 72% of the caregivers decided in favor of the 
patch. At week 24, the most frequently assigned reasons 
in favor of the patch were: simplicity of the schedule and 
ease of use. The more speciﬁ  c reasons given for patch 
preference included greater self-sufﬁ  ciency, fewer or no 
adverse events, and more convenient handling. Those 
caregivers preferring the capsules declared most frequently, 
ease of use.
Health-related quality of life
No clinical trial has investigated the effect of the rivastigmine 
patch on health-related quality of life (HRQOL). Nor has the 
effect on HRQOL of treatment with rivastigmine capsules 
been investigated (Institute for Quality and Efﬁ  ciency in 
Health Care 2007).
Cost
In Germany, the daily therapy cost of rivastigmine capsules 
was  5.50 in 2006. In comparison, the daily therapy cost 
of donezepil amounted to  3.72 and galantamine to  4.31 
(Schwabe and Paffrath 2007). In a recent meta-analysis 
of comparative health economic evaluations a cost 
saving effect was found using rivastigmine capsules. 
In patients with mild to moderate AD these models 
estimated a cost per quality-adjusted life year gain, rang-
ing from £16.000–£46.000 (NICE 2007). Unfortunately, no 
evaluations for rivastigmine patch treatment are currently 
available. In Germany, the cost of the small and large patch 
is approximately  4 per patch.
Conclusion
In recent years, TDS have become an increasingly important 
treatment option for the application of certain drugs (Priano 
et al 2006). This trend is due especially to continuous drug 
delivery, leading to consistent drug plasma level, improved 
tolerance, greater systemic bioavailability, and is also due to 
avoiding the ﬁ  rst-pass effect, simple usage, easy scheduling, 
and strong adhesiveness. Most available patches result in 
only rare disadvantages, such as skin irritations.
The rivastigmine patch, the ﬁ  rst patch for treating 
mild to moderate AD, was approved in July 2007 in 
the US. In the IDEAL study the 10 cm2 patch signiﬁ  -
cantly improved cognition, global impression, activities 
of daily living, motor processing speed, and attention 
and visual tracking, compared with placebo (Priano 
et al 2006; Winblad et al 2007a; Winblad et al 2007b). 
Concomitantly, patients treated with the 10 cm2 patch 
developed approximately two-thirds fewer gastrointestinal 
side effects, such as vomiting and nausea, compared with 
patients treated with rivastigmine capsules (3–12 mg/day). 
In contrast to the capsules, the incidence of adverse events 
is not significantly different compared with placebo 
(Winblad et al 2007a; Winblad et al 2007b). The lower 
incidence of adverse events may be the result of reduced 
ﬂ  uctuation of the drug plasma level due to continuous 
drug delivery, because the acute, centrally-mediated 
gastrointestinal effects correlated with the maximum 
plasma level and the time it took to reach this peak after oral 
administration (Jann et al 2002; Darvesh et al 2003). The 
infrequent gastrointestinal side effects after administration 
of the patch might compensate for the higher incidence 
of nausea and vomiting in the therapy with rivastigmine 
capsules compared with donezepil and galantamine, which 
is probably associated with inhibition of the AchE and 
the BchE of rivastigmine (Inglis 2002). Well designed 
clinical trials should investigate the incidence of adverse 
events with the rivastigmine patch, compared with the oral 
formulation of donezepil and galantamine.
In the IDEAL study, due to gastrointestinal effects 
approximately 75% fewer patients treated with the 10 cm2 
patch discontinued the therapy compared with patients 
receiving capsules (Winblad et al 2007b). This should con-
tribute to a better compliance of patients suffering from AD 
(Cummings and Winblad 2007). This result has proved to 
be very important, because consistent therapy is essential, 
in order to reduce the risks of rapid cognitive deterioration, 
increasing medical and healthcare costs, and the resignation 
of caregivers (Blesa et al 2007; Small and Dubois 2007). 
Compared with the capsules, another advantage of the patch 
is the easier dosing schedule with one increase of the dosage 
after 4 weeks only.
A disadvantage of the rivastigmine patch is higher 
therapy costs compared to capsules. In Germany the annual 
cost for the 9.5 mg/24 h patch accounts for  1,424 compared 
with  1,318 for treatment with 12 mg capsules daily (based 
on Red List price, 2008:  352.25 per 90 9.5 mg/24 h patch 
package vs  202.79 per 112 6 mg capsules package).
Furthermore, there is less clinical experience compared 
with treatment with oral AchEI, and the evidence of clinical 
efﬁ  cacy is based on only a few trials. However, the good 
efﬁ  cacy, rare systemic adverse events, dynamic skin toler-
ance, handling ease, and the satisfaction of caregivers, means 
that the new rivastigmine patch is an important step in the 
treatment of AD.Drug Design, Development and Therapy 2008:2 253
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